Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

The Michael J Fox Foundation

- PMLiVE

Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan

The company has been given manufacturing and marketing authorisation for the therapy

- PMLiVE

Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms

The platform will passively collect data to understand treatment responses in everyday life

- PMLiVE

Mission Therapeutics advances Parkinson’s disease candidate

The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

- PMLiVE

Biogen expands portfolio in deal with Alcyone Therapeutics

The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders

- PMLiVE

PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

The US-based company develops light-based therapies for neurodegenerative conditions

- PMLiVE

GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

- PMLiVE

Sanofi’s investigational frexalimab shows promise in relapsing MS study

Approximately 2.9 million people worldwide are affected by the neurological disease

- PMLiVE

Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

The neurodegenerative condition currently affects nearly ten million people worldwide

- PMLiVE

Roche and Ascidian enter neurological disease partnership worth over $1.8bn

More than three billion people worldwide were living with a neurological condition in 2021

- PMLiVE

Tiziana shares promising results for intranasal foralumab in secondary progressive MS

The neurological disease is estimated to affect 2.8 million people globally

- PMLiVE

Tiziana shares promising results for intranasal foralumab in multiple sclerosis

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Cerevel Therapeutics shares positive phase 3 results for tavapadon in Parkinson’s disease

The progressive neurodegenerative disease affects seven million people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links